Abbott Laboratories (ABT) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pac...
Abbott Laboratories's revenue increased 5.7% year over year, from $41.95B to $44.33B.
Net income decreased 51.3% over the same period, from $13.40B to $6.52B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 113% in total.
Total debt decreased by 21.6% to $9.90B.
The debt-to-equity ratio stands at 0.19, indicating a conservative leverage profile.
Operating cash flow grew 11.8% to $9.57B.
Abbott Laboratories maintains a healthy net profit margin of 14.7%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $29.87B+51.4% | $4.13B | $16.45B | $4.70B | $4.22B | $72.09B | $14.48B | $37.48B |
| Q1 FY2024 | $9.96B-66.6% | $1.23B | $5.50B | $1.39B | $1.02B | $72.47B | $12.58B | $38.81B |
| Q2 FY2024 | $20.34B+104.1% | $2.53B | $11.28B | $3.06B | $2.98B | $73.02B | $13.14B | $39.32B |
| Q3 FY2024 | $30.98B+52.3% | $4.17B | $17.21B | $4.91B | $5.69B | $74.36B | $12.82B | $39.80B |
| Q1 FY2025 | $10.36B-66.6% | $1.32B | $5.89B | $1.69B | $1.42B | $81.45B | $12.74B | $48.81B |
| Q2 FY2025 | $21.50B+107.6% | $3.10B | $12.18B | $3.75B | $3.46B | $84.00B | $12.93B | $50.56B |
| Q3 FY2025 | $32.87B+52.9% | $4.75B | $18.47B | $5.80B | $6.25B | $84.18B | $11.60B | $50.95B |
| Q1 FY2026 | $11.16B-66.0% | $1.08B | $6.27B | $1.34B | $1.31B | $110.43B | $29.64B | $52.06B |
Balance Sheet Summary (Latest Period)
Total Assets
$86.71B
Total Liabilities
$34.58B
Total Equity
$52.13B
Cash & Equivalents
$8.94B
Total Debt
$9.90B
Current Assets
$26.00B
Current Liabilities
$16.50B
Retained Earnings
$49.78B